BioXcel Therapeutics, Inc. Common Stock

Day range

$0.07 – $0.09

Open

$0.09

Prev close

$0.07

Volume

47.48M

Market cap

—

Shares out

—

• Delisting determinationSep 1, 2026

  Nasdaq had determined to delist the Company's common stock ... as a result of the Company's commencement of voluntary proceedings under Chapter 11 ... Trading ... will be suspended ... on September 8, 2026, and a Form 25-NSE will be filed.

• Voluntary bankruptcyAug 28, 2026

  On August 27, 2026 (the "Petition Date"), BioXcel Therapeutics, Inc. (the "Company") and its subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (together with the Company, the "Debtors") each filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

• Covenant violationAug 25, 2026

  The Lenders agreed to reduce the Credit Agreement's minimum liquidity covenant to require minimum cash liquidity of $250,000 (instead of $3.0 million). The Company is required to, on or prior to August 31, 2026 (extended from August 28, 2026, as was required under the Thirteenth Amendment), enter into definitive agreements with respect to one or more transactions acceptable to Lenders that (A) would result in the repayment of all loan and other obligations under the Credit Agreement or (B) is an alternative capital solutions transaction on terms and conditions acceptable to the Lenders.

• Credit facilityAug 24, 2026

  On August 21, 2026, BioXcel Therapeutics, Inc. (the "Company") entered into the Thirteenth Amendment to Credit Agreement and Guaranty (the "Thirteenth Amendment"), which amended the Credit Agreement and Guaranty, dated April 19, 2022, as amended (the "Credit Agreement"), by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the "Lenders"), and Oaktree Fund Administration LLC, as administrative agent.

• Credit facilityAug 11, 2026

  On August 10, 2026, BioXcel Therapeutics, Inc. entered into the Twelfth Amendment to Credit Agreement and Guaranty and First Amendment to Security Agreement (the 'Twelfth Amendment'), which amended the Credit Agreement and Guaranty, dated April 19, 2022, as amended (the 'Credit Agreement'), by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the 'Lenders'), and Oaktree Fund Administration LLC, as administrative agent.

Days to cover

1.0

Short interest

6.12M

Avg volume

7.19M

As of Aug 31, 2026 · reported to FINRA twice monthly.

• Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
  positiveZacks Investment Research· Aug 31, 2026
• [Latest] Global AI in Drug Repurposing Market Size/Share Worth USD 10.56 Billion by 2035 at a 23.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
  positiveGlobeNewswire Inc.· Jul 21, 2026
• Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
  negativeGlobeNewswire Inc.· Mar 23, 2026
• BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
  neutralGlobeNewswire Inc.· Mar 10, 2026
• BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
  positiveGlobeNewswire Inc.· Oct 13, 2025